Breaking News, Collaborations & Alliances

Ryvu and nCage Partner to Develop Next-Generation ADC Platform

Aim to develop a novel drug delivery system (DDS) that could improve the efficacy and safety of current ADCs.

Author Image

By: Charlie Sternberg

Associate Editor

Ryvu Therapeutics and nCage Therapeutics have announced a research collaboration to develop a next-generation antibody-drug conjugate (ADC) platform.   nCage’s TRAP cage platform, a novel drug delivery system (DDS), could enhance the efficacy and safety of current ADCs. By utilizing virus-like particles (VLPs), the platform can improve the antibody-to-drug ratio (DAR) of ADCs, potentially leading to greater efficacy and reduced side effects.   “This collaboration is an exciting opportunity t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters